ReviewCancers2022
Approaches to the Management of Metastatic Adenoid Cystic Carcinoma.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Stereotactic radiosurgery for intracranial and spinal adenoid cystic carcinoma: systematic review and illustrative case presentation.Journal of neuro-oncology · 2025Pooled it
- Article
- Comparison of 5-year survival rates and prognostic factors between adenoid cystic carcinoma and squamous cell carcinoma of the maxillary sinus: a SEER database analysis.Translational cancer research · 2026Article
- Case Report: Long-term disease control with immunotherapy in primary mandibular adenoid cystic carcinoma presenting with pulmonary metastasis.Frontiers in immunology · 2026Article
- Case Report: A rare case of long-term survival in primary pulmonary adenoid cystic carcinoma with bilateral renal and chest wall metastases.Frontiers in oncology · 2026Article
- Case Report: A rare case of over 45 years' survival in a patient with tonsillar adenoid cystic carcinoma.Frontiers in oncology · 2026Article
- Multimodal treatment for multifocal metastatic maxillary adenoid cystic carcinoma: A case report.Oncology letters · 2025Article
- Tracheobronchial adenoid cystic carcinoma: a two-center retrospective analysis of clinical features and survival outcomes.European journal of medical research · 2025Article
- Article
- Adenoid cystic carcinoma brain metastases treated with stereotactic radiosurgery: A single institution retrospective cohort study and comprehensive literature review.Neurosurgical review · 2025Review
- Survival outcomes of pulmonary metastasis-directed local therapy in adenoid cystic carcinoma.Cancer · 2025Article
- Epidermal Growth Factor Receptor (EGFR) Downregulation by Cetuximab in Salivary Duct Carcinoma: A Case Report.Cureus · 2025Article
- Clinical Outcomes With Notch Inhibitors in Notch-Activated Recurrent/Metastatic Adenoid Cystic Carcinoma.Cancer medicine · 2025Article
- Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma.Journal for immunotherapy of cancer · 2025Article
- Article
- Primary Intracranial Adenoid Cystic Carcinoma: A Case Report.JNMA; journal of the Nepal Medical Association · 2025Article
- Real-world insights on a rare disease: adenoid cystic carcinoma of the breast.Ecancermedicalscience · 2025Article
- Locoregional Recurrence in Adenoid Cystic Carcinoma of the Breast: A Retrospective, Multicenter Study (KROG 22-14).Cancer research and treatment · 2025Article
- Article
- Current insights and future directions of Li-Fraumeni syndrome.Discover oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High rates of recurrence and distant metastasis are a foremost challenge in the management of adenoid cystic carcinoma (ACC), occurring in approximately 40% of all ACC patients. Despite the morbidity and mortality resulting from recurrent/metastatic (R/M) disease, there are no FDA-approved systemic agents for these patients. In this review, we summarize pertinent ACC pathophysiology and its implications for different systemic treatment regimens in R/M ACC. We review the evidence for the most widely used systemic agents - cytotoxic chemotherapy and tyrosine kinase inhibitors (TKIs) targeting VEGFR - in addition to immune checkpoint inhibitors and non-TKI biologic agents. Exciting emerging targets for R/M ACC, including inhibitors of Notch signaling, stemness, PRMT5, and Axl, are also discussed. Lastly, we review local therapies for small-volume lung disease in patients with oligometastatic ACC, specifically pulmonary metastasectomy and stereotactic body radiation therapy (SBRT). Future development of targeted molecular agents which exploit the underlying biology of this disease may yield novel therapeutic options to improve clinical outcomes in patients with R/M ACC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.